The Tauopathies drugs in development market research report provides comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tauopathies. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Tauopathies - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tauopathies and features dormant and discontinued products.

GlobalData tracks 51 drugs in development for Tauopathies by 45 companies/universities/institutes. The top development phase for Tauopathies is preclinical with 29 drugs in that stage. The Tauopathies pipeline has 44 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Tauopathies pipeline products market are: Aprinoia Therapeutics, Novartis and Korea Institute of Science and Technology.

The key targets in the Tauopathies pipeline products market include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT), Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1), and Heat Shock Protein 70 (HSP70).

The key mechanisms of action in the Tauopathies pipeline product include Microtubule Associated Protein Tau (Neurofibrillary Tangle Protein or Paired Helical Filament Tau or MAPT) Inhibitor with 20 drugs in Phase II. The Tauopathies pipeline products include five routes of administration with the top ROA being Oral and ten key molecule types in the Tauopathies pipeline products market including Small Molecule, and Monoclonal Antibody.

Tauopathies overview

Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of tau protein into neurofibrillary or gliofibrillary tangles in the human brain. Tau protein normally stabilizes microtubules, which are essential for intracellular transport and communication. However, when tau becomes hyperphosphorylated or misfolded, it dissociates from microtubules and forms insoluble aggregates that impair neuronal function and survival. Tauopathies can present with various clinical phenotypes, such as cognitive impairment, behavioral changes, dementia, parkinsonism, and language disorders. Tauopathies can be classified based on the predominant tau isoforms that are present in the inclusions (3R, 4R or equal 3R:4R ratio). Tau biomarkers in cerebrospinal fluid and blood, as well as imaging techniques, can help in the diagnosis and evaluation of tauopathies. Currently, there is no effective treatment for tauopathies, but several tau-targeted therapies are in development.

For a complete picture of Tauopathies’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.